Bausch + Lomb Corporation NYSE:BLCO

Bausch + Lomb stock price today

$14.979
-2.99
-16.64%
Financial Health
0
1
2
3
4
5
6
7
8
9

Bausch + Lomb stock price monthly change

+12.73%
month

Bausch + Lomb stock price quarterly change

+12.73%
quarter

Bausch + Lomb stock price yearly change

+9.17%
year

Bausch + Lomb key metrics

Market Cap
6.20B
Enterprise value
7.90B
P/E
831.5
EV/Sales
2.09
EV/EBITDA
13.41
Price/Sales
1.54
Price/Book
0.82
PEG ratio
-8.59
EPS
-0.96
Revenue
4.31B
EBITDA
508M
Income
-337M
Revenue Q/Q
18.04%
Revenue Y/Y
13.22%
Profit margin
0.16%
Oper. margin
5.84%
Gross margin
59.69%
EBIT margin
5.84%
EBITDA margin
11.78%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Bausch + Lomb stock price history

Bausch + Lomb stock forecast

Bausch + Lomb financial statements

Average Price Target
Last Year

$22.43

Potential upside: 49.73%

Based on estimate of 7 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Bausch + Lomb Corporation (NYSE:BLCO): Profit margin
Jun 2023 1.03B -32M -3.09%
Sep 2023 1.00B -84M -8.34%
Dec 2023 1.17B -54M -4.6%
Mar 2024 1.09B -167M -15.2%
Bausch + Lomb Corporation (NYSE:BLCO): Earnings per share (EPS)
2024-02-21 0.17 0.24
2024-05-01 0.09 0.07
Bausch + Lomb Corporation (NYSE:BLCO): Debt to assets
Jun 2023 11315000000 4.28B 37.87%
Sep 2023 13068000000 6.18B 47.33%
Dec 2023 13442000000 6.52B 48.52%
Mar 2024 13293000000 6.56B 49.38%
Bausch + Lomb Corporation (NYSE:BLCO): Cash Flow
Jun 2023 -24M -28M 90M
Sep 2023 48M -1.88B 1.81B
Dec 2023 15M -135M 86M
Mar 2024 41M -57M 12M

Bausch + Lomb alternative data

Bausch + Lomb Corporation (NYSE:BLCO): Employee count
Aug 2023 12,900
Sep 2023 13,000
Oct 2023 13,000
Nov 2023 13,000
Dec 2023 13,000
Jan 2024 13,000
Feb 2024 13,000
Mar 2024 13,300
Apr 2024 13,300
May 2024 13,300
Jun 2024 13,300
Jul 2024 13,300

Bausch + Lomb other data

5.54% -7.25%
of BLCO is owned by hedge funds
19.38M -25.36M
shares is hold by hedge funds

Bausch + Lomb Corporation (NYSE:BLCO): Insider trades (number of shares)
Period Buy Sel
Aug 2024 32250 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
SAUNDERS BRENT L director, officer: CEO and Chai..
Common Shares, No Par Value 32,250 $15.66 $505,067
Sale
BAUSCH HEALTH COMPANIES INC. 10 percent owner
Common Shares, No Par Value 4,550,357 $17.06 $77,606,339
Sale
BAUSCH HEALTH COMPANIES INC. 10 percent owner
Common Shares, No Par Value 35,000,000 $17.06 $596,925,000
Wednesday, 30 October 2024
seekingalpha.com
zacks.com
zacks.com
Monday, 14 October 2024
fool.com
investopedia.com
Sunday, 22 September 2024
benzinga.com
Tuesday, 17 September 2024
zacks.com
Monday, 16 September 2024
fool.com
investopedia.com
investors.com
proactiveinvestors.com
Wednesday, 31 July 2024
seekingalpha.com
zacks.com
zacks.com
Wednesday, 24 July 2024
zacks.com
Monday, 17 June 2024
businesswire.com
Monday, 10 June 2024
businesswire.com
Monday, 3 June 2024
businesswire.com
Wednesday, 29 May 2024
businesswire.com
Tuesday, 28 May 2024
businesswire.com
Wednesday, 1 May 2024
seekingalpha.com
businesswire.com
Monday, 29 April 2024
businesswire.com
Thursday, 25 April 2024
businesswire.com
Wednesday, 24 April 2024
zacks.com
Thursday, 18 April 2024
businesswire.com
Monday, 15 April 2024
Business Wire
Monday, 8 April 2024
Zacks Investment Research
Monday, 25 March 2024
Zacks Investment Research
Thursday, 21 March 2024
Zacks Investment Research
  • What's the price of Bausch + Lomb stock today?

    One share of Bausch + Lomb stock can currently be purchased for approximately $14.98.

  • When is Bausch + Lomb's next earnings date?

    Unfortunately, Bausch + Lomb's (BLCO) next earnings date is currently unknown.

  • Does Bausch + Lomb pay dividends?

    No, Bausch + Lomb does not pay dividends.

  • How much money does Bausch + Lomb make?

    Bausch + Lomb has a market capitalization of 6.20B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 10.03% to 4.15B US dollars. Bausch + Lomb made a loss 260M US dollars in net income (profit) last year or $0.07 on an earnings per share basis.

  • What is Bausch + Lomb's stock symbol?

    Bausch + Lomb Corporation is traded on the NYSE under the ticker symbol "BLCO".

  • What is Bausch + Lomb's primary industry?

    Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.

  • How do i buy shares of Bausch + Lomb?

    Shares of Bausch + Lomb can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Bausch + Lomb have?

    As Jul 2024, Bausch + Lomb employs 13,300 workers.

  • When Bausch + Lomb went public?

    Bausch + Lomb Corporation is publicly traded company for more then 3 years since IPO on 6 May 2022.

  • What is Bausch + Lomb's official website?

    The official website for Bausch + Lomb is bausch.com.

  • Where are Bausch + Lomb's headquarters?

    Bausch + Lomb is headquartered at 520 Applewood Crescent, Vaughan, ON.

  • How can i contact Bausch + Lomb?

    Bausch + Lomb's mailing address is 520 Applewood Crescent, Vaughan, ON and company can be reached via phone at +90 56957700.

  • What is Bausch + Lomb stock forecast & price target?

    Based on 7 Wall Street analysts` predicted price targets for Bausch + Lomb in the last 12 months, the avarage price target is $22.43. The average price target represents a 49.73% change from the last price of $14.98.

Bausch + Lomb company profile:

Bausch + Lomb Corporation

bausch.com
Exchange:

NYSE

Full time employees:

13,000

Industry:

Medical - Instruments & Supplies

Sector:

Healthcare

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

520 Applewood Crescent
Vaughan, ON L4K 4B4

CIK: 0001860742
ISIN: CA0717051076
CUSIP: 071705107